These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37661184)

  • 1. Regulation of epidermal growth factor receptor tyrosine kinase inhibitor resistance via Ambra1-mediated autophagy in non-small cell lung cancer.
    Chen YH; Yang Y; Xu LJ; Deng Y; Fu JW
    J Physiol Pharmacol; 2023 Jun; 74(3):. PubMed ID: 37661184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
    Cao Q; You X; Xu L; Wang L; Chen Y
    Autophagy; 2020 Jul; 16(7):1236-1247. PubMed ID: 31448672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor.
    Zhao FY; Han J; Chen XW; Wang J; Wang XD; Sun JG; Chen ZT
    Int J Mol Med; 2016 Jul; 38(1):183-91. PubMed ID: 27177336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
    Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
    Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells.
    Lin Y; Higashisaka K; Shintani T; Maki A; Hanamuro S; Haga Y; Maeda S; Tsujino H; Nagano K; Fujio Y; Tsutsumi Y
    Sci Rep; 2020 Mar; 10(1):4748. PubMed ID: 32179851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
    Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
    Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation.
    Ma C; Zhang X; Mo X; Yu Y; Xiao Z; Wu J; Ding L; Lei C; Zhu Y; Zhang H
    Phytomedicine; 2024 Mar; 125():155351. PubMed ID: 38232540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.
    Han J; Zhao F; Zhang J; Zhu H; Ma H; Li X; Peng L; Sun J; Chen Z
    Int J Oncol; 2016 May; 48(5):1855-67. PubMed ID: 26936292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
    Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
    Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
    Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
    BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FoxO3a inhibiting expression of EPS8 to prevent progression of NSCLC: A new negative loop of EGFR signaling.
    Wen Q; Jiao X; Kuang F; Hou B; Zhu Y; Guo W; Sun G; Ba Y; Yu D; Wang D; Zhang F; Qiao HC; Wang S; Tang S; Qiao H
    EBioMedicine; 2019 Feb; 40():198-209. PubMed ID: 30738830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
    Zou Y; Ling YH; Sironi J; Schwartz EL; Perez-Soler R; Piperdi B
    J Thorac Oncol; 2013 Jun; 8(6):693-702. PubMed ID: 23575415
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
    Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 19. [STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma].
    Huang L; Hou M; Liu J; Li Y; Shen W; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):771-781. PubMed ID: 36419390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
    Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
    J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.